Epidemiology of viral hepatitis and hepatocellular carcinoma.

PubWeight™: 10.00‹?› | Rank: Top 0.1%

🔗 View Article (PMC 3338949)

Published in Gastroenterology on May 01, 2012

Authors

Hashem B El-Serag1

Author Affiliations

1: Section of Gastroenterology and Hepatology, Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas, USA. hasheme@bcm.edu

Associated clinical trials:

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study (ROLFH) | NCT01831037

Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With Doxorubicin | NCT03452553

Articles citing this

(truncated to the top 100)

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19

Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol (2013) 3.12

Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer (2016) 2.91

Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res (2014) 2.51

Substantial contribution of extrinsic risk factors to cancer development. Nature (2015) 2.46

Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol (2013) 2.30

Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer (2014) 2.26

Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med (2014) 2.24

Global control of hepatitis C: where challenge meets opportunity. Nat Med (2013) 2.22

Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut (2014) 2.19

Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int (2015) 1.92

Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol (2014) 1.69

Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol (2014) 1.66

Prolactin prevents hepatocellular carcinoma by restricting innate immune activation of c-Myc in mice. Proc Natl Acad Sci U S A (2014) 1.63

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int (2015) 1.59

Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology (2014) 1.58

Hepatic Arterial Infusion of Low-Density Lipoprotein Docosahexaenoic Acid Nanoparticles Selectively Disrupts Redox Balance in Hepatoma Cells and Reduces Growth of Orthotopic Liver Tumors in Rats. Gastroenterology (2015) 1.53

Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and females. CA Cancer J Clin (2016) 1.53

Underestimation of liver-related mortality in the United States. Gastroenterology (2013) 1.46

Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol (2015) 1.45

Gender differences in incidence and outcomes of urothelial and kidney cancer. Nat Rev Urol (2015) 1.42

Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS (2014) 1.41

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract (2013) 1.41

Resource utilization and survival among Medicare patients with advanced liver disease. Dig Dis Sci (2014) 1.40

World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology (2015) 1.38

Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2013) 1.36

Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther (2013) 1.26

Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol (2014) 1.17

MicroRNAs in hepatocellular carcinoma: regulation, function, and clinical implications. ScientificWorldJournal (2013) 1.16

Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res (Phila) (2013) 1.14

Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer (2014) 1.12

Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol (2015) 1.11

Role of NADPH oxidases in liver fibrosis. Antioxid Redox Signal (2014) 1.10

Modulation of hypoxia-signaling pathways by extracellular linc-RoR. J Cell Sci (2014) 1.09

Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumour Biol (2013) 1.08

Statins Reduce the Risk of Cirrhosis and its Decompensation in CHB Patients? Am J Gastroenterol (2017) 1.08

The Influence of Hepatitis B Viral Load and Pre-S Deletion Mutations on Post-Operative Recurrence of Hepatocellular Carcinoma and the Tertiary Preventive Effects by Anti-Viral Therapy. PLoS One (2013) 1.05

NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol (2014) 1.04

Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res (2014) 1.03

miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. World J Gastroenterol (2014) 1.03

PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs. PPAR Res (2012) 1.03

Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives. World J Gastroenterol (2013) 1.02

Referral patterns and treatment choices for patients with hepatocellular carcinoma: a United States population-based study. J Am Coll Surg (2013) 1.02

Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine (Baltimore) (2015) 1.01

Immunotherapeutic approaches to hepatocellular carcinoma treatment. Liver Cancer (2012) 1.00

Hepatitis B virus X protein inhibits tumor suppressor miR-205 through inducing hypermethylation of miR-205 promoter to enhance carcinogenesis. Neoplasia (2013) 1.00

A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids (2013) 0.99

The wound healing, chronic fibrosis, and cancer progression triad. Physiol Genomics (2014) 0.99

HBx-related long non-coding RNA DBH-AS1 promotes cell proliferation and survival by activating MAPK signaling in hepatocellular carcinoma. Oncotarget (2015) 0.99

Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res (2015) 0.99

Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol (2015) 0.98

Maturation-associated destabilization of hepatitis B virus nucleocapsid. J Virol (2013) 0.97

Comparison of clinical characteristics and survival after surgery in patients with non-B and non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma. J Cancer (2013) 0.97

Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer (2013) 0.97

MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway. Cell Death Dis (2015) 0.96

Sequencing assays for failed genotyping with the versant hepatitis C virus genotype assay (LiPA), version 2.0. J Clin Microbiol (2013) 0.96

Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States. PLoS One (2015) 0.96

Experimental therapies for yellow fever. Antiviral Res (2012) 0.96

Propensity score analysis demonstrated the prognostic advantage of anatomical liver resection in hepatocellular carcinoma. World J Gastroenterol (2014) 0.96

Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells. Oncotarget (2015) 0.95

Aflatoxin contamination in wheat flour samples from golestan province, northeast of iran. Iran J Public Health (2012) 0.95

Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer. Oncotarget (2015) 0.95

Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer (2014) 0.94

Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma. Free Radic Biol Med (2014) 0.94

Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol (2013) 0.94

Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol (2014) 0.94

β-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation. Cancer Lett (2013) 0.94

Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview. World J Gastroenterol (2014) 0.94

Hepatocellular carcinoma: Review of disease and tumor biomarkers. World J Hepatol (2016) 0.94

Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry. World J Gastroenterol (2014) 0.93

Treatment of hepatitis C virus infection in the future. Clin Transl Med (2013) 0.93

Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. Proc Natl Acad Sci U S A (2014) 0.93

Deacetylation by SIRT1 Reprograms Inflammation and Cancer. Genes Cancer (2013) 0.92

Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis. AIDS (2016) 0.92

Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma. World J Gastroenterol (2013) 0.92

Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacol Sin (2015) 0.92

Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol (2016) 0.91

Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan. J Cancer (2014) 0.91

Biomarker-based MicroRNA Therapeutic Strategies for Hepatocellular Carcinoma. J Clin Transl Hepatol (2014) 0.90

DNA damage response and sphingolipid signaling in liver diseases. Surg Today (2015) 0.90

A specific cholesterol metabolic pathway is established in a subset of HCCs for tumor growth. J Mol Cell Biol (2013) 0.90

Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention. Emerg Microbes Infect (2013) 0.89

The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol (2013) 0.89

Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection. Oncotarget (2015) 0.89

Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci (2014) 0.89

Galectin-1-Induced Autophagy Facilitates Cisplatin Resistance of Hepatocellular Carcinoma. PLoS One (2016) 0.89

Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget (2016) 0.88

Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol (2016) 0.88

Incidence of hepatocellular carcinoma according to hepatitis B virus genotype in Alaska Native people. Liver Int (2016) 0.88

Hepatocellular carcinoma. Cold Spring Harb Perspect Med (2015) 0.88

Overexpression of Chemokine (C-X-C) ligand 1 (CXCL1) associated with tumor progression and poor prognosis in hepatocellular carcinoma. Cancer Cell Int (2014) 0.88

Mutual antagonism between circadian protein period 2 and hepatitis C virus replication in hepatocytes. PLoS One (2013) 0.88

International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer (2016) 0.88

Clinical presentation and survival of Asian and non-Asian patients with HCV-related hepatocellular carcinoma. Dig Dis Sci (2013) 0.87

Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med (2015) 0.87

Hepatitis B and C in African Americans: current status and continued challenges. Clin Gastroenterol Hepatol (2013) 0.87

Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon (2012) 0.87

Effect of a liver cancer education program on hepatitis B screening among Asian Americans in the Baltimore-Washington metropolitan area, 2009-2010. Prev Chronic Dis (2014) 0.86

Loss of estrogen-related receptor α promotes hepatocarcinogenesis development via metabolic and inflammatory disturbances. Proc Natl Acad Sci U S A (2013) 0.86

Articles cited by this

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78

Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 10.31

Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology (2004) 8.36

Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum Suppl (1987) 6.47

Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med (2002) 6.20

Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature (1991) 6.04

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol (2007) 4.73

A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev (1994) 4.62

The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol (2006) 4.17

Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50

Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst (2008) 3.27

HCV-associated liver cancer without cirrhosis. Lancet (1995) 3.23

Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology (2007) 3.22

Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology (2003) 2.97

Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol (2002) 2.94

Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther (2008) 2.90

Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology (2001) 2.90

Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. Arch Intern Med (2009) 2.79

A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer (1998) 2.64

Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology (2007) 2.57

Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology (2011) 2.42

Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev (2012) 2.38

Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol (1998) 2.21

Liver microsomal metabolism of aflatoxin B 1 to a reactive derivative toxic to Salmonella typhimurium TA 1530. Cancer Res (1972) 2.18

Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology (2009) 1.95

Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis (2006) 1.84

A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer (2005) 1.76

Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (2010) 1.70

Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology (2010) 1.69

Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology (2010) 1.68

Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol (2010) 1.67

Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol (2005) 1.53

Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med (1990) 1.53

Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. J Natl Cancer Inst (2004) 1.44

Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol (2009) 1.43

Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. Proc Natl Acad Sci U S A (2007) 1.41

Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int (2011) 1.39

Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology (2004) 1.36

Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol (2010) 1.36

The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: A basis for primary prevention in Guinea-Conakry, West Africa. J Gastroenterol Hepatol (2002) 1.32

Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology (2006) 1.31

A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Int J Cancer (1995) 1.26

Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer (2011) 1.21

Interaction between cigarette smoking and hepatitis B and C virus infection on the risk of liver cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2010) 1.15

The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol (2003) 1.12

Molecular evolution of hepatitis viruses. Intervirology (1999) 1.04

Hepatitis B virus and cancer prevention. Recent Results Cancer Res (2011) 1.03

Effect of human immunodeficiency virus and antiretrovirals on outcomes of hepatitis C: a systematic review from an epidemiologic perspective. Clin Gastroenterol Hepatol (2007) 0.97

Development of hepatocellular carcinoma after clearance of hepatitis C virus with interferon therapy. West J Med (1997) 0.96

Association between chronic hepatitis C infection and hepatocellular carcinoma. Lancet (1995) 0.94